Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
RNA modifications are crucial in regulating mRNA translation. This Review provides a comprehensive overview of the molecular mechanisms underlying RNA modifications in mRNA translation regulation, and discusses the diagnostic and therapeutic potentials of targeting RNA modifications for liver cancer management.
Our Ig Nobel Prize-winning smart toilet research confronts societal taboos and uses humour as a gateway to advance serious dialogue about health technology. It is a call to action to embrace innovation, foster richer scientific discussions and support pioneering research for tangible health advancements.
A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.
In this Review, Argüero and Sifrim describe the core pathophysiological mechanisms involved in gastro-oesophageal reflux disease (GERD). They also discuss the implications for clinical management of GERD.
Gastrointestinal issues are common in autism spectrum disorders (ASDs). This Review provides a comprehensive overview of the clinical and mechanistic connections between ASDs and gastrointestinal disorders and how these data might be utilized for future research and novel therapeutic targets.
In this Review, Danne and colleagues describe the roles of neutrophils in inflammatory bowel disease, as well as their functions in host–microbiota interactions.
Coeliac disease is a chronic inflammatory disease triggered by gluten consumption in individuals with a genetic susceptibility. These Evidence-Based Guidelines provide recommendations for improving the health care of the patients and discuss future perspectives.
2023 was the most memorable year on record for obesity. The American Academy of Pediatrics recognized the complex, multifactorial nature of obesity and the broad range of treatments necessary to care for pediatric patients. The first-ever triple agonist and high-potency oral GLP1 agonist was introduced with unprecedented results.
In 2023, there were significant advancements in trials of interventions to reduce mortality and morbidity from alcohol-related liver disease, spanning the entire spectrum of disease: primary prevention to reduce overall alcohol-related harm, secondary prevention to attenuate fibrosis progression and tertiary prevention using antibiotics for severe alcohol-associated hepatitis.
Fermented foods have gained renewed popularity owing to their health-promoting potential. This Review discusses the mechanisms underlying the benefits of fermented foods in gut health and disease, highlighting how specific fermented food microorganisms, food components and bioactive compounds exert their effects. A future outlook on research is also detailed.
Metastatic colorectal cancer is a heterogeneous disease associated with poor patient outcomes. Although the past decade has seen few first-line treatment advances, key studies published in 2023 established new options for late-line therapy of the disease with and without oncogenic drivers, thus expanding the continuum of care in metastatic colorectal cancer.
Gut microbiota has a vital role in mechanisms involved in overweight and obesity, including host metabolism and energy expenditure. This Review describes the physiology of white and brown adipose tissue and provides timely insights into the gut microbiota–adipose tissue axis.
Important studies published in 2023 outlined new agents and strategies for the management of inflammatory bowel disease. Therapeutic ambitions for the management of inflammatory bowel disease were raised by the success of combinations of biologic agents in ulcerative colitis and early surgical resection in Crohn’s disease.
New light is being shed on the interactions between the gut microbiome, cancer cell signalling and the host immune response. With this knowledge, microbiota-based approaches for improving cancer prevention, prognostication and therapy have started to materialize and will contribute to reducing the global cancer burden.
Steatotic liver disease has emerged as an important risk factor for cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease. Successful treatment of steatotic liver disease might also be effective in preventing these cardiometabolic diseases.
